clinical trial · NCT05536141
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Clear Cell Renal Cell CarcinomaSolid TumorscasdatifanCabozantinibZimberelimabIpilimumab
brief summary
The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab or zimberelimab and ipilimumab in participants with ccRCC in the dose expansion stage.
started
Oct 26, 2022
primary completion
Mar 1, 2029
completion
Mar 1, 2029
last updated
Mar 30, 2026
official title
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol